Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2022-01-07 Earnings Release
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
Earnings Release Classification · 1% confidence The document is an 'Ad-hoc' release dated January 7, 2022, from MorphoSys AG. It reports preliminary sales figures for 2021 and provides financial guidance for 2022, including specific revenue ranges, expense forecasts (R&D, SG&A), and gross margin expectations. This content—the initial announcement of key financial performance metrics and forward-looking guidance for the upcoming year—is characteristic of an Earnings Release (ER). Although it mentions that the full fourth quarter and full year 2021 results will be published later (March 16, 2022), this specific document serves as the preliminary announcement of key figures and guidance, fitting the definition of an Earnings Release (ER) better than a simple Report Publication Announcement (RPA) because it contains substantive, forward-looking financial data, not just a notice that a report is available. FY 2021
2022-01-07 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' regarding BlackRock, Inc.'s change in voting rights percentage in MorphoSys AG, referencing German Securities Trading Act (WpHG) articles. This content directly relates to changes in significant share ownership thresholds, which aligns perfectly with the definition for Major Shareholding Notification (MRQ). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific type of ownership disclosure.
2021-12-23 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership, voting rights percentages, and details of financial instruments (options, swaps) held by a major shareholder (The Goldman Sachs Group, Inc.) in MorphoSys AG, referencing German Securities Trading Act (WpHG) articles. This structure perfectly matches the definition of a notification regarding changes in significant share ownership thresholds, which corresponds to the Major Shareholding Notification category (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the content is a formal notification of a holding change, not the results of a vote (DVA).
2021-12-14 English
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
Regulatory Filings Classification · 1% confidence The document is a news release dated December 12, 2021, announcing that MorphoSys AG presented data from its Phase 2 MANIFEST Study evaluating pelabresib at the 63rd American Society of Hematology Annual Meeting (ASH 2021). It details clinical trial results (spleen volume reduction, symptom scores, adverse events) and includes forward-looking statements and contact information. This format—a press release summarizing scientific/clinical updates and often referencing a conference presentation—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is announcing key data points rather than just the publication of a report (RPA), the most fitting category for a company announcing clinical trial results and key findings outside of a formal earnings call is the Earnings Release (ER) category, as these announcements often accompany or precede quarterly financial reporting periods, or the Regulatory Filings (RNS) as a general news announcement. Given the content is a detailed scientific update presented at a major medical meeting, and it is disseminated via DGAP (a common channel for regulatory/corporate news), RNS is a strong candidate. However, since it focuses on presenting data that drives investor interest, similar to an earnings highlight, ER is also plausible. Given the structure and the explicit mention of DGAP-News and the nature of presenting clinical data, RNS (Regulatory Filings/General Corporate News) is the most appropriate fallback for a non-standard financial report announcement.
2021-12-12 English
MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL
Regulatory Filings Classification · 1% confidence The document is a press release dated December 11, 2021, issued by MorphoSys AG and Incyte, announcing 'Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab...'. It details clinical trial data (OS, ORR, CR rates) and mentions presentations at the American Society of Hematology Annual Meeting (ASH 2021). This content structure—announcing new clinical/study results outside of a formal quarterly or annual financial filing—is characteristic of an Earnings Release (ER) or a general announcement. Since it is focused on presenting new scientific/clinical data rather than summarizing overall financial performance for a period (which would be ER or IR), and it is not a transcript (CT) or a formal presentation deck (IP), it fits best as a general announcement related to corporate activity. However, given the context of financial reporting databases, announcements of clinical trial data that are not part of a formal earnings report often fall under the general 'Regulatory Filings' (RNS) category if no other specific category applies, or sometimes an Earnings Release (ER) if it's tied to a reporting period. Since this is a specific scientific/clinical data release, and not a standard financial earnings release (ER) or an interim report (IR), and it's not a transcript (CT), the most appropriate general category for a significant, non-standard corporate update that doesn't fit the other specific scientific/legal/governance codes is RNS (Regulatory Filings/Miscellaneous Announcement). The document length is substantial (24k chars), indicating it is the full announcement, not just a brief notice (ruling out RPA).
2021-12-11 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership, voting rights percentages, and the nature of instruments held by a major shareholder (The Goldman Sachs Group, Inc.). This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership thresholds. Although the header mentions 'Voting Rights Announcements', the content structure (reporting changes in holdings crossing thresholds) aligns best with the 'Major Shareholding Notification' code (MRQ) in the provided schema, as it details the resulting voting rights structure after an acquisition/disposal. It is not a general regulatory filing (RNS) because it is highly specific to share ownership changes.
2021-12-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.